About LDS

About LDS

Lyotropic Delivery Systems (LDS) is based on the know-how and many years of research of Prof. Nissim Garti. Garti’s technology led to LDS’s establishment in 2013, and since then has extended its expertise in the field of delivery, developing new and more advanced technologies and strengthening the company’s IP.

An extensive portfolio of early to commercial stage projects

LDS develops, under a licensing agreement, several blockbuster products for an international pharmaceutical company ranked in the top five companies in the industry. Our pipeline includes several projects at both early and late stages, including R&D, pre-clinical, and clinical phases, covered by broad intellectual property rights of several platform and numerous specific patents; some of which are granted and some under examination.

We have licensed our delivery technology to companies in various fields for different active compounds including parenteral (Neoprol, propofol), ophthalmic (OphRx, various molecules) oral (Ananda, cannabinoids), and topical (Nannovate, terbinafine) applications.

Built on the know-how of Prof. Nissim Garti

Prof. Garti, a full professor since 1999 at the Hebrew University of Jerusalem, has been honored as the recipient of the Ratner Family Chair of Chemistry, and has earned many prestigious international awards among which are the Rockefeller Foundation award, the International Food Science award, the Surfactants in Solution (SIS) award, as well as several of the American Oil Chemists’ Society awards, and more. He has served as a consultant to more than 15 global companies in the fields of food chemistry, cosmetics, health care and nutraceuticals. Prof. Garti has published 15 books, over 30 review articles, and more than 410 peer-reviewed original manuscripts. He submitted ca 90 patents and has served on the scientific boards of several companies and scientific journals.
LDS’s technology grew from Prof. Garti’s know-how and profound understanding in the field of colloids and surfaces, interfacial science, dispersed systems, and interfacial science, backed by more than 30 years of scientific research.

Leadership Team

The team at LDS includes experienced researchers, all with a deep understanding of surface and colloid science, and profound knowledge of liquid formulations. Their combination of expertise, innovative spirit, and passion for science enables our achievements and novelty in the world of delivery systems. The company’s lead team includes:

Prof. Nissim Garti

Founder and CEO

Prof. Garti’s background includes over 40 years of ‘product-oriented research’ at the Casali Institute of Applied Chemistry, at the Hebrew University of Jerusalem.
Read more

Dr. Sharon Garti-Levi

Co-founder and VP R&D

Dr. Garti-Levi joined LDS in 2015 and leads the innovation, research, and development efforts of the company.
Read more

Mr. Yaacov Michlin


Yaacov Michlin is the president of LDS, responsible for the business development of the company.
Read more

Mr. Shaya Kramer

Business Advisor

Shaya Kramer is the CEO and the main shareholder of Peerless Foods, which started in the 1950s in Melbourne, Australia.
Read more

Scientific Advisory Board

Prof. Holmberg is a member of The Royal Swedish Academy of Sciences (Nobel Prize-awarding academy), The Royal Swedish Academy of Engineering Sciences, and The Royal Society of Arts and Sciences in Gothenburg. Prof. Holmberg was Professor of Surface Chemistry at Chalmers from 1998 to 2016, and 1991–1998 he was directed the Institute for Surface Chemistry in Stockholm, a research institute with more than 80 industrial members from around 10 countries. Before that he spent 15 years in the pharmaceutical and the chemical industry, including several years as Research Director of the surfactants company Berol Nobel. Through the years he has supervised 18 PhD students and many postdoctoral fellows. He has published 320 papers in peer-reviewed journals, and written or edited 7 books.
Mr. Lawrence Gozlan currently serves as the Life Sciences Investment Manager at Jagen Pty Ltd, an international private investment organization. Mr. Gozlan was responsible for the largest Life Sciences investment portfolio in Australia, as the Portfolio Manager at QIC (Queensland Investment Corporation), an investment fund with over AU$60 billion under management. Mr. Gozlan was previously the senior biotechnology analyst at Foster Stockbroking and advised numerous life sciences companies in corporate finance at Deloitte. Mr. Gozlan is a board member of several public and private healthcare companies and has presented at numerous international life science conferences. He holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne.
Prof. Maria Francesca Ottaviani is a Chemistry Professor at the Department of Pure and Applied Sciences (DiSPeA) of the University of Urbino. Her main fields of expertise are the characterization of liquid-liquid bio-interfaces, mainly as drug carriers, and their interactions with the bioenvironment, as well as solid-liquid hybrid interphases all studied using the unique technique of Magnetic Resonance Techniques. She has been working as Senior Associate Scientist at the Department of Chemistry, Columbia University, New York, since 1991. She collaborates with several foreign universities and researches around the world. She is the author of 235 peer-reviewed papers in international journals.

Partnership and Licensing 

LDS is licensing its unique delivery platform for various products and applications. We partner with companies looking to enrich their pipeline, renew their patent life, bring innovation, and overcome the difficulties they face using traditional delivery systems.